Preparation and preclinical evaluation of (177)Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389005%3A_____%2F12%3A00374499" target="_blank" >RIV/61389005:_____/12:00374499 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/12:43904240
Result on the web
<a href="http://dx.doi.org/10.1016/j.nucmedbio.2011.07.001" target="_blank" >http://dx.doi.org/10.1016/j.nucmedbio.2011.07.001</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.nucmedbio.2011.07.001" target="_blank" >10.1016/j.nucmedbio.2011.07.001</a>

Result language
angličtina
Original language name
Preparation and preclinical evaluation of (177)Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors
Original language description
Objectives: Nimotuzumab (h-R3) is a humanized monoclonal antibody (mAb) which recognizes the external domain of the epidermal growth factor receptor (EGFR) with high specificity. It was demonstrated that h-R3 has a unique clinical profile for immunotherapy of adult gliomas and pediatric pontine gliomas. The aim of this work was to evaluate the conjugate (177)Lu-h-R3 as a potential radioimmunoconjugate for radioimmunotherapy (RIT) of tumors overexpressing EGER.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—

Project
<a href="/en/project/2B06165" target="_blank" >2B06165: Production of positron emitting radionuclides Y-86 and I-124 for PET-imaging, study of their separation from the irradiated matrix and labelling of chosen prospective carriers</a><br>
Continuities
Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)